CliffBio
small molecule

XTANDI

ENZALUTAMIDE

Loss of exclusivityFebruary 2037latest FDA-listed patent expiry
CompanyAstellas Pharma Us →See this company's full patent-cliff portfolio

Drug detail

Brand nameXTANDI
Active ingredientENZALUTAMIDE
Strength80MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2020
Marketing statusRX

Listed patents

PatentExpiresType
12161628February 2037use U-4101
11839689September 2033product
12447128September 2033use U-4314
12502357September 2033use U-4365
7709517August 2027substance, product
8183274August 2026use U-3763
9126941May 2026use U-3763

Regulatory exclusivity

CodeExpires
I-926November 2026

More from Astellas Pharma Us

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.